<DOC>
	<DOCNO>NCT01333137</DOCNO>
	<brief_summary>P276-00 novel , potent , small-molecule , flavone-derived Cdk 4 D1 , Cdk1 B , Cdk9 T inhibitor , potent cytotoxic effect chemosensitive chemoresistant cancer cell lines.This study plan compare efficacy standard chemotherapy regimen gemcitabine carboplatin administer without P276-00 subject advance triple negative breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Comparing Gemcitabine Carboplatin With Without P276-00 Subjects With Metastatic Triple Negative Breast Cancer , With Run-in Escalating Dose P276-00 Added Gemcitabine Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Females age ≥18 year . 2 . Histologically document metastatic triple negative breast cancer ( triple negative breast cancer Phase I ) 3 . Two few chemotherapy regimen advance disease ( limit prior regimens Phase I ) 4 . ECOG performance score 1 less 5 . Presence measurable disease RECIST 1.1 criterion ( Phase I portion ) 6 . Ability understand willingness sign write informed consent document ( ICD ) 7 . Full recovery prior treatment toxicity Common Terminology Criteria Adverse Events ( CTCAE V.4 ) Grade ≤ 1 1 . Prior chemotherapy biologic/targeted anticancer agent within 4 week study drug administration 2 . Prior radiation therapy within 6 week study drug administration 3 . Subject know active CNS metastasis and/or carcinomatous meningitis . However , subject CNS metastasis complete course therapy would eligible study provide clinically stable least 1 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis new neurological symptom attributable CNS metastasis ( 2 ) steroid use minimize surround brain edema . 4 . Prior therapy gemcitabine platinum agent ( Phase I part ) 5 . Prior therapy Cdk/cyclin inhibitor flavone derivative 6 . QTc interval &gt; 450 msec ( use Fridericia 's formula ) 7 . Any acute illness include uncontrolled diabetes , symptomatic otherwise uncontrolled cardiac disease ( coronary artery disease , arrhythmia , congestive heart failure ) illness judgment investigator would introduce additional medical risk 8 . Visceral crisis include extensive liver disease &gt; 50 % parenchymal involvement lymphangitic pulmonary disease 9 . History prior malignancy except properly treat basal cell squamous cell carcinoma skin , situ cervical cancer , situ breast cancer 10 . Expected survival le 3 month 11 . Hemoglobin &lt; 9.0 gm/dL 12 . Absolute neutrophil count &lt; 1500/mm3 13 . Platelet count &lt; 100,000/mm3 14 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 × institutional upper limit normal ( ULN ) 15 . Total bilirubin , &gt; 1.5 × institutional ULN 16 . Serum creatinine &gt; 1.5 mg/dL 17 . Subjects know infection human immunodeficiency virus ( HIV ) , tuberculosis , Hepatitis C Hepatitis B 18 . Pregnant lactate woman 19 . Women childbearing potential willing use approve method contraception sign ICD , entire study least 4 week completion study follow withdrawal study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Triple negative breast cancer</keyword>
</DOC>